Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136195 · ClinicalTrials.gov registry record · Phase 1
Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
A Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol Consumption, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 2
- Study locations
NCT06136195: Recruiting Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol Consumption, sponsored by Yale University.
NCT06136195 is a Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol Consumption that is actively recruiting participants, run by Yale University. The registered enrollment target is 63 participants, below the 1,822-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06136195, a Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol Consumption, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.
Primary Outcome
The number of drinks consumed during the adlib session will be recorded
Conditions Studied
Interventions
- DRUG Mavoglurant
Study Locations (2)
Connecticut
- Connecticut Mental Health Center (SAC and SATU) - New Haven
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
What NCT06136195 shows while recruiting
NCT06136195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,822-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Alcohol Use Disorder (AUD) appearing as the primary indexed condition, and to 1 intervention - of which Mavoglurant is the first listed.
NCT06136195 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06136195 about?
NCT06136195 is a clinical study titled "Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers". The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.
What is the current status of trial NCT06136195?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2024-07-01. Estimated completion is 2026-05-31.
What conditions does trial NCT06136195 study?
This clinical trial studies the following conditions: Alcohol Use Disorder (AUD), Alcohol Consumption, Heavy Drinker.
What interventions are being tested in trial NCT06136195?
The interventions under investigation include: Mavoglurant (DRUG).
Who is sponsoring clinical trial NCT06136195?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136195 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder (AUD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06136195's enrollment target sits among peer trials
63 20th of 30 higher than 10 of 30 other Alcohol Use Disorder (AUD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder (AUD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
RECRUITING · Phase 1
-
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
RECRUITING · Phase 1
-
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
RECRUITING · Phase 1
-
Diclofenac Dose Response Study
RECRUITING · Phase 1
-
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Recovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI